Author/Authors :
Zare Shahneh، Fatemeh نويسنده Drug Applied Research Center, Tabriz, Iran, Tabriz University of Medical Sciences, Tabriz, Iran. , , Mohammadian، Mozhdeh نويسنده Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran. , , Babaloo، Zohreh نويسنده Drug Applied Research Center, Tabriz, Iran, Tabriz University of Medical Sciences, Tabriz, Iran. , , Baradaran، Behzad نويسنده Department of Immunology, Tabriz University of Medical Sciences, Immunology research center, Tabriz, Iran Baradaran, Behzad
Abstract :
Behçet Disease (BD) is an autoimmune disorder with recurrent ocular, vascular, central nervous system, articular, mucocutaneous, and gastrointestinal manifestations with unclear etiology and pathogenesis. The further characterization of inflammatory features of Behçet’s disease may eventually lead to development of better treatment options. Clinical and laboratory observations suggested an important role of IL-17, IL-21 and neutrophil-mediated process in the pathogenesis of BD. New therapeutic modalities target specific and nonspecific suppression of the immune system. The various non-specific immunosuppressive drugs, used either alone or in combinations, frequently fail to control inflammation or maintain remissions. Due to encouraging clinical results (i.e. Antigenic specification, prolonged survival with acceptable levels of toxicity); antibody-based drugs could be effective for the clinical management of Behçet’s disease.
